Efficacy and Safety of AXS-05 in MDD 🧠

Created using ChatSlide

This presentation offers a comprehensive overview of AXS-05, a novel therapeutic approach, highlighting its mechanism and relevance to Major Depressive Disorder (MDD). It details the GEMINI trial, emphasizing the Phase 3 design, patient demographics, and study duration. Attendees will gain insights into the efficacy results, including improvements in symptoms and remission rates. The safety profile section covers common adverse effects and highlights the treatment's tolerability and absence...